Insider Transactions in Q2 2025 at Revolution Medicines, Inc. (RVMD)
Insider Transaction List (Q2 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 30
2025
|
Mark A Goldsmith |
BUY
Exercise of conversion of derivative security
|
Direct |
37,000
+7.36%
|
$0
$0.54 P/Share
|
|
Jun 26
2025
|
Alexis Borisy |
BUY
Grant, award, or other acquisition
|
Direct |
3,142
+0.13%
|
-
|
|
Jun 26
2025
|
Lorence H. Kim |
BUY
Grant, award, or other acquisition
|
Direct |
3,142
+4.12%
|
-
|
|
Jun 26
2025
|
Sushil Patel |
BUY
Grant, award, or other acquisition
|
Direct |
3,142
+11.98%
|
-
|
|
Jun 26
2025
|
Sandra Horning |
BUY
Grant, award, or other acquisition
|
Direct |
3,142
+3.15%
|
-
|
|
Jun 26
2025
|
Frank Clyburn |
BUY
Grant, award, or other acquisition
|
Direct |
2,806
+22.37%
|
-
|
|
Jun 26
2025
|
Elizabeth M Anderson |
BUY
Grant, award, or other acquisition
|
Direct |
3,142
+11.92%
|
-
|
|
Jun 26
2025
|
Flavia Borellini |
BUY
Grant, award, or other acquisition
|
Direct |
3,142
+11.16%
|
-
|
|
Jun 20
2025
|
Jeff Cislini General Counsel |
SELL
Open market or private sale
|
Direct |
1,912
-3.41%
|
$74,568
$39.61 P/Share
|
|
Jun 16
2025
|
Lin Wei Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,173
-2.34%
|
$84,747
$39.83 P/Share
|
|
Jun 16
2025
|
Stephen Michael Kelsey |
SELL
Open market or private sale
|
Direct |
4,289
-1.46%
|
$167,271
$39.83 P/Share
|
|
Jun 16
2025
|
Jack Anders Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,170
-1.88%
|
$84,630
$39.83 P/Share
|
|
Jun 16
2025
|
Jeff Cislini General Counsel |
SELL
Open market or private sale
|
Direct |
1,878
-3.24%
|
$73,242
$39.83 P/Share
|
|
Jun 16
2025
|
Mark A Goldsmith |
SELL
Open market or private sale
|
Direct |
13,496
-3.05%
|
$526,344
$39.83 P/Share
|
|
Jun 16
2025
|
Margaret A Horn Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
3,510
-2.28%
|
$136,890
$39.83 P/Share
|